Spots Global Cancer Trial Database for A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.
Official Title: A Phase I, Multi-center, Open-label, Study of LXS196, an Oral Protein Kinase C Inhibitor, in Patients With Metastatic Uveal Melanoma
Study ID: NCT02601378
Conditions
Study Description
Brief Summary: This study was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of LXS196 as a single agent and in combination with HDM201 in patients with metastatic uveal melanoma.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Columbia University Medical Center, New York, New York, United States
Novartis Investigative Site, Westmead, New South Wales, Australia
Novartis Investigative Site, Paris, , France
Novartis Investigative Site, Leiden, , Netherlands
Novartis Investigative Site, Oslo, , Norway
Novartis Investigative Site, Madrid, , Spain
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
